case_images: PMC9794418_01
case_images: Fundus image and fundus autofluorescence of right eye on initial presentation (a, d), right eye 6 years later:prior to fluocinolone acetonide intravitreal implant:(b, e), and right eye 15 months after fluocinolone acetonide intravitreal implant (c, f).
case_images: CRIOPM2022-3962221.001.jpg
case_images: PMC9794418_01_CRIOPM2022-3962221.001.jpg
case_images: fig1
case_images: OD (Figure 1). Upon evaluation 15 months after fluocinolone acetonide implant placement, there was no recurrence of inflammation evident (Figures 1 and 2), and repeat assessment at 20 months revealed stability of findings.
case_images: Optical coherence tomography (OCT) of the right eye on initial presentation (a), right eye 6 years later:prior to fluocinolone acetonide intravitreal implant:(b), and right eye 15 months after fluocinolone acetonide intravitreal implant (c).
case_images: CRIOPM2022-3962221.002.jpg
case_images: PMC9794418_01_CRIOPM2022-3962221.002.jpg
case_images: fig2
case_images: Optical coherence tomography (OCT) revealed temporal outer retinal atrophic changes without fluid OD (Figure 2). On fluorescein angiography, these lesions exhibited early hypofluorescence with late staining at the edges in both eyes. Upon evaluation 15 months after fluocinolone acetonide implant placement, there was no recurrence of inflammation evident (Figures 1 and 2), and repeat assessment at 20 months revealed stability of findings.